GB2110533A - Compositions containing alkaloid derivatives - Google Patents
Compositions containing alkaloid derivatives Download PDFInfo
- Publication number
- GB2110533A GB2110533A GB08220293A GB8220293A GB2110533A GB 2110533 A GB2110533 A GB 2110533A GB 08220293 A GB08220293 A GB 08220293A GB 8220293 A GB8220293 A GB 8220293A GB 2110533 A GB2110533 A GB 2110533A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutically acceptable
- alkaloid derivative
- cytostatic alkaloid
- derived
- acceptable cytostatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims description 14
- 229930013930 alkaloid Natural products 0.000 claims abstract description 50
- 230000001085 cytostatic effect Effects 0.000 claims description 40
- 239000000824 cytostatic agent Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 30
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims description 16
- 241001233914 Chelidonium majus Species 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- GHKISGDRQRSCII-ZOCIIQOWSA-N chelidonine Chemical compound C1=C2[C@H]3N(C)CC4=C(OCO5)C5=CC=C4[C@H]3[C@@H](O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-ZOCIIQOWSA-N 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 9
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 claims description 8
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 claims description 8
- GHKISGDRQRSCII-UHFFFAOYSA-N chelidonine Natural products C1=C2C3N(C)CC4=C(OCO5)C5=CC=C4C3C(O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-UHFFFAOYSA-N 0.000 claims description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 claims description 5
- VINIVXVRXVXNTR-UHFFFAOYSA-N Chelidonin Natural products CN1Cc2c3OCOc3ccc2C4C(O)Cc5c6OCOc6ccc5C14 VINIVXVRXVXNTR-UHFFFAOYSA-N 0.000 claims description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 claims description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims description 5
- 229960003147 reserpine Drugs 0.000 claims description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 claims description 5
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 claims description 4
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 claims description 4
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940039750 aconitine Drugs 0.000 claims description 4
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 claims description 4
- HYBRYAPKQCZIAE-UHFFFAOYSA-N allocryptopine Chemical compound C1=C2CCN(C)CC3=C(OC)C(OC)=CC=C3CC(=O)C2=CC2=C1OCO2 HYBRYAPKQCZIAE-UHFFFAOYSA-N 0.000 claims description 4
- NGFLTEGALWMQIJ-UHFFFAOYSA-N allocryptopine Natural products COc1ccc2CC(=O)c3cc4OCOc4cc3CN(C)CCc2c1OC NGFLTEGALWMQIJ-UHFFFAOYSA-N 0.000 claims description 4
- HUIJAZQRYSCNED-UHFFFAOYSA-N alpha-allo-cryptopine Natural products C1CN(C)CC2=C(OC)C(OC)=CC=C2CC(=O)C2=CC(OC)=C(OC)C=C21 HUIJAZQRYSCNED-UHFFFAOYSA-N 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 claims description 4
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims description 3
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 claims description 3
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims description 3
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 8
- 230000000979 retarding effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 18
- 239000000126 substance Substances 0.000 abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 6
- 206010036030 Polyarthritis Diseases 0.000 abstract description 3
- 229940035676 analgesics Drugs 0.000 abstract description 3
- 239000000730 antalgic agent Substances 0.000 abstract description 3
- 206010003246 arthritis Diseases 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 208000030428 polyarticular arthritis Diseases 0.000 abstract description 3
- 230000002285 radioactive effect Effects 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 230000002980 postoperative effect Effects 0.000 abstract description 2
- 230000029936 alkylation Effects 0.000 abstract 1
- 238000005804 alkylation reaction Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 28
- 239000011575 calcium Substances 0.000 description 19
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 238000003745 diagnosis Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- -1 fangohinolin Chemical compound 0.000 description 12
- 0 C[n]1c(*)cnc1 Chemical compound C[n]1c(*)cnc1 0.000 description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 11
- 239000007795 chemical reaction product Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 206010027476 Metastases Diseases 0.000 description 10
- 229960004397 cyclophosphamide Drugs 0.000 description 9
- 230000009401 metastasis Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000003327 cancerostatic effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 206010016334 Feeling hot Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 3
- 208000002260 Keloid Diseases 0.000 description 3
- 206010023330 Keloid scar Diseases 0.000 description 3
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000002152 alkylating effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000001117 keloid Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 150000003014 phosphoric acid esters Chemical class 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003660 reticulum Anatomy 0.000 description 3
- 229940084560 sanguinarine Drugs 0.000 description 3
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- ZCTJIMXXSXQXRI-UHFFFAOYSA-N 9-[2-[(6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-4,5-dimethoxyphenoxy]-1,2,10-trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC2=C(CC3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-UHFFFAOYSA-N 0.000 description 2
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003017 phosphorus Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WEEFNMFMNMASJY-UHFFFAOYSA-M 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 WEEFNMFMNMASJY-UHFFFAOYSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- ZUPIHFVWSWCKSD-UHFFFAOYSA-N 6-deoxyswietenine Natural products COC(=O)CC1C(C)(C)C(OC(=O)C(=CC)C)C2C=C3C(CCC4(C)C3CC(=O)OC4c5cocc5)C1(C)C2=O ZUPIHFVWSWCKSD-UHFFFAOYSA-N 0.000 description 1
- BKRMCDAOAQWNTG-UHFFFAOYSA-N 9-methoxy-5,11-dimethyl-6h-pyrido[4,3-b]carbazole Chemical compound C1=NC=C2C(C)=C(C=3C(=CC=C(C=3)OC)N3)C3=C(C)C2=C1 BKRMCDAOAQWNTG-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DFOCUWZXJBAUSQ-UHFFFAOYSA-N Berbamine Natural products O1C(C(=CC=2)O)=CC=2CC(C=23)N(C)CCC3=CC(OC)=C(OC)C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 DFOCUWZXJBAUSQ-UHFFFAOYSA-N 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LLEJIEBFSOEYIV-UHFFFAOYSA-N Chelerythrine Natural products C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WRCBXHDQHPUVHW-UHFFFAOYSA-N Deoxyharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCC(C)C)CC(=O)OC)C4C2=CC2=C1OCO2 WRCBXHDQHPUVHW-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HAVJATCHLFRDHY-KSZYUSJVSA-N Harringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HAVJATCHLFRDHY-KSZYUSJVSA-N 0.000 description 1
- HAVJATCHLFRDHY-UHFFFAOYSA-N Harringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HAVJATCHLFRDHY-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- LMFKRLGHEKVMNT-ZIEJDFEHSA-N Heliotrine Natural products C1C[C@H](O)[C@H]2C(COC(=O)[C@](O)(C(C)C)[C@H](C)OC)=CCN21 LMFKRLGHEKVMNT-ZIEJDFEHSA-N 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 206010053132 Lymphangiosis carcinomatosa Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- NLSTZAFFNDSJGQ-UHFFFAOYSA-N Matrin Natural products O=C1CCCN2CC3CCNC4CCCC(C34)C12 NLSTZAFFNDSJGQ-UHFFFAOYSA-N 0.000 description 1
- URPVDDXMEZAEJY-UHFFFAOYSA-N Melicopicine Natural products C1=CC=C2C(=O)C3=C(OC)C(OC)=C(OC)C(OC)=C3N(C)C2=C1 URPVDDXMEZAEJY-UHFFFAOYSA-N 0.000 description 1
- NKZNKBLXNLBATF-UHFFFAOYSA-N Melicopine Natural products CN1C2=CC=CC=C2C(=O)C(C=C2OC)=C1C1=C2OCO1 NKZNKBLXNLBATF-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000003166 Opuntia robusta Nutrition 0.000 description 1
- 244000218514 Opuntia robusta Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241001573961 Parotis Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- CGBZTBVMBAQHHC-UHFFFAOYSA-N Thalicarpin Natural products COc1cc(CC2N(C)CCc3cc(OC)c(OC)cc23)c(Oc4c(OC)ccc5CC6N(C)CCc7cc(OC)c(OC)c(c67)c45)cc1OC CGBZTBVMBAQHHC-UHFFFAOYSA-N 0.000 description 1
- SVQMVSCWYACSCP-UHFFFAOYSA-N Thalidasin Natural products O1C(C(=C(OC)C=C23)OC)=C2CCN(C)C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 SVQMVSCWYACSCP-UHFFFAOYSA-N 0.000 description 1
- SVQMVSCWYACSCP-KYJUHHDHSA-N Thalidasine Chemical compound C([C@@H]1N(C)CCC2=C(C(=C(OC)C=C21)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 SVQMVSCWYACSCP-KYJUHHDHSA-N 0.000 description 1
- SAHRHSGBQUZFQR-UHFFFAOYSA-N Thalidasine Natural products COc1ccc2CC3Cc4c(CN3C)cc(OC)c(OC)c4Oc5c6CCN(C)C(Cc7ccc(Oc1c2)cc7)c6cc(OC)c5OC SAHRHSGBQUZFQR-UHFFFAOYSA-N 0.000 description 1
- SSEUDFYBEOIWGF-AWEZNQCLSA-N Tylophorine Chemical compound C1=C(OC)C(OC)=CC2=C(C=C(C(OC)=C3)OC)C3=C(C[C@H]3N(CCC3)C3)C3=C21 SSEUDFYBEOIWGF-AWEZNQCLSA-N 0.000 description 1
- SSEUDFYBEOIWGF-CQSZACIVSA-N Tylophorine Natural products C1=C(OC)C(OC)=CC2=C(C=C(C(OC)=C3)OC)C3=C(C[C@@H]3N(CCC3)C3)C3=C21 SSEUDFYBEOIWGF-CQSZACIVSA-N 0.000 description 1
- ASCBRLGHWVZBMG-UHFFFAOYSA-N UNPD71813 Natural products COC=1C(=O)C=2C(O)=C(OC)C(OC)=CC=2OC=1C(C=C1)=CC=C1OC1OC(CO)C(O)C(O)C1O ASCBRLGHWVZBMG-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- UXYJCYXWJGAKQY-OAHLLOKOSA-N ac1lf4k6 Chemical compound C1C2=C3OCOC3=CC=C2C[C@H]2N1CCC1=C2C=C(OCO2)C2=C1 UXYJCYXWJGAKQY-OAHLLOKOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 description 1
- QRCWKBAFKDYSFR-UHFFFAOYSA-N chelirubine Natural products COc1cc2cc3OCOc3cc2c4N(C)C(O)c5c6OCOc6ccc5c14 QRCWKBAFKDYSFR-UHFFFAOYSA-N 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- NGZXDRGWBULKFA-VSGBNLITSA-N curine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 NGZXDRGWBULKFA-VSGBNLITSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000040 effect on leukemia Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- ZUPIHFVWSWCKSD-JDYHYRCCSA-N febrifugin Natural products COC(=O)C[C@H]1C(C)(C)[C@@H](OC(=O)C(=CC)C)[C@@H]2C=C3[C@@H](CC[C@]4(C)[C@H]3CC(=O)O[C@@H]4c5cocc5)[C@@]1(C)C2=O ZUPIHFVWSWCKSD-JDYHYRCCSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229930005325 imidazole alkaloid Natural products 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- ZTKMNYDOFAYRAK-UHFFFAOYSA-N isoacronycine Natural products CN1C2=CC=CC=C2C(=O)C2=C1C=C1OC(C)(C)C=CC1=C2OC ZTKMNYDOFAYRAK-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002576 laryngoscopy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005162 left hepatic lobe Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GJPZDZHEZDANAG-UHFFFAOYSA-N methyl n-(1h-benzimidazol-2-yl)carbamate;propan-2-yl n-(3,4-diethoxyphenyl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.CCOC1=CC=C(NC(=O)OC(C)C)C=C1OCC GJPZDZHEZDANAG-UHFFFAOYSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XDKNUCQYHGFFFE-UHFFFAOYSA-N pendulin Natural products COc1cc2ccc3c(OC)c(OC)c(OC)cc3c2c(OC)c1O XDKNUCQYHGFFFE-UHFFFAOYSA-N 0.000 description 1
- 108010034040 pendulin Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 229930002337 quinolizidine alkaloid Natural products 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229930003352 steroid alkaloid Natural products 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- DEXCWVBNPJKCOQ-UHFFFAOYSA-N tetrahydropseudocoptisine Natural products C1=C2C3CC(C=C4OCOC4=C4)=C4CN3CCC2=CC2=C1OCO2 DEXCWVBNPJKCOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003578 thiophosphoric acid amides Chemical class 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 150000004788 tropolones Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/224—Phosphorus triamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/564—Three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Radio active isotopes, fluorescent substances or substances absorbing X rays may be added to alkaloid derivatives. The alkaloids may be used also as analgesics for the treatment of polyarthritis and as a post-operative anti-inflammatory substance. The new derivatives of the formula <IMAGE> where Y : O, S, N; X : N, O; n : 1-3; and (III) represent an isoquinolin-comprising alkaloid, may be prepared by reacting one or a plurality of alkaloids of the formula (III) with alkylation agents.
Description
SPECIFICATION
Composition and method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types
The invention is directed to a composition and a method for diagnosing and for therapeutic treatment of tumors and infectious diseases. The composition is also useful as analgesics for the treatment of polyarthritis and as post-operative anti-inflammatory agents.
The invention is directed to a method of diagnosing the presence of tumor cells and for therapeutic treatment of tumors and infectious diseases and to a composition for carrying out the method. The diagnostic and therapeutic reagent is a pharmaceutically acceptable cytostatic derivative of an alkaloid which may also be carcinostatic. The terminology "pharmaceutically acceptable" means at least non-toxic to the host. The alkaloid itself can be cytostatic as well as carcinostatic. The alkaloid derivative is formed by coupling the alkaloid with a compound which may be generically referred as an alkylating reagent which will alkylate the alkaloid, which does not interfere with the cytostatic or carcinostatic property of the alkaloid or which is itself cytostatic or carcinostatic. Such alkylating reagents may contain phosphorus and/or nitrogen atoms.
The method of the invention involves administering pharmaceutically effective amounts of said derivative or water soluble pharmaceutically acceptable salts of said derivatives to the host.
Administering the reagent may be undertaken by injection or intravenously or subcutaneously. The amounts of the reagent which are administered to the host depend own various factors such as body weight of the host, the stage of disease in the host and the exact nature of the disease and can range from 0.5 mg or less up to 680 mg or more. Generally, the reagents are administered as solutions. A typical aqueous solution to be administered to the host will contain 0.5 mg of the alkaloid derivative in 1 ml of dilute saline solution. The rule in determining dosages for therapeutic purposes is an amount effective to at least retard tumor cell multiplication and, for purposes of diagnosis, to allow accumulation in the tumor tissue of amounts of the reagent sufficient to be detectable.Detection of the accumulated reagent may be undertaken by chemical means, surgery, spectroscopy and/or radiation detection methods well known in the art.
Many alkaloids are described below for use in accordance with the invention to sustain or impart the following common characteristics to the cytostatic derivatives of alkaloids used in accordance with the invention Stimulation to the cellular defense mechanism; antagonistic to tumor cells and cells attacked by virus and other antigens; having an affinity and capacity for accumulation in tumor tissue.
Alkaloid derivatives of thiophosphoric acid exhibit pharmacological effectiveness as a sytostatic.
The word "cytostatic" herein means tending to retard cellular activity and multiplication. Water-soluble salts of those alkaloid derivatives can now be made. Barberine, sanguinarine, salts of alkaloids of the large celandine can be rendered water-soluble as can salts of the bisbenzylisoquinoline-alkaloids, including curine, fangohinolin, tetrandine, pendulin, thalidasine, aporphinebenzylisoquinoline-alkaloids, e.g., thalicarpin, ibogo-alkaloids, e.g., 20-hydroxyvoacamidin, indole-indoline-alkaloids, e.g., leorosidin, lurosin, vinkaleukoblastin, leurocristin, tropolone alkaloids, e.g., colchicine, isoquinolinealkaloids, e.g., liriodenin, O-methylatherolin, oxypurpurin, chelidonin, protopine, stylopin, allocryptopine, coptisin, chelerytrin, corysamin, chelidimerin, homochelidonin, methoxychelidonin, chelilutin, chelirubin, narciclasin, talicarpin, pakistanien, pacistanamine, pensylwanin, pensylwanamin, berberine, sanguinarine, caffeine, nitydyne, faraganin, steroid-alkaloids, indole-isoquinoline-alkaloids, e.g., 9-methoxyellipticin, ellipticin, indole-alkaloids, e.g., reserpine, quinolineindolizidin-alkaloids, e.g., campothecin, pyrolin-alkaloids, e.g., tatrofan, pyrolizidin-alkaloids, e.g., heliotrin, acridone-alkaloids, e.g., melicopin, acromycin, normelioepidin, phenanthroindolizidine-alkaloids, e.g., tylophorine, tylocrebin, imidazole-alkaloids, e.g., pilocarpine, quinolizidine-alkaloids, e.g., matrin, oxymatrin, cryptoleurin, chinazolon-alkaloids, e.g., febrifugin, benzuzepin-alkaloids, e.g., cephalotaxin, deoxyharringtonin, homcharringtonin, harringtonin and others.
The thiophosphoric derivatives of alkaloids are also known in the form of free bases and are of interest here. Examples of such known derivatives are thiophosphoric acid-di-(ethyleneimido)-Nberberinol-ethylamide, thiophosphoric acid-tri-(n-sanguinarinol)-ethyiamide as well as thiosphophoric acid amido derivatives of the total alkaloids of the condensed isoquinoline systems of the large celandine.
These thiophosphoric derivatives of alkaloids which exhibit cytostatic effectiveness are only sparingly soluble in water. In order to use the derivatives in water, which is preferred to organic solvents for the preparation of injection solutions, the derivatives must be rendered water soluble.
The desired water solubility can be imparted to the active alkaloid derivatives without sacrificing their cytostatic effect and without other undesirable side effects by converting the derivatives to salts of pharmaceutically acceptable acids. The alkaloid, which can also be carcinostatically effective, is coupled with a second carcinostatic agent, preferably from the group consisting of alkylantiene, antimetabolites, antibiotics, and other nitrogen- or phosphorus-containing organic compounds; and the resulting product is converted into a pharmaceutically useable salt. As used herein, the word "carcinostatic" means tending to retard epithelial malignant tumor growth and multiplication.The bases thiophosphoric acid-tri-(N-sanguinarinol)-ethylamine, thiophosphoric acid-di-(ethyleneimido)-N herberinol-ethylamide as well as N,N',N"-triethylene-thiophosphoramide derivatives of the condensed isoquinoline system-alkaloids are selected from the large celandine (that is, chelidonium majus L.). The aforementioned compounds have proven to be especially suitable as alkaloid components.
The following are especially useful as the second carcinostatic agent for the conversion:
Nitrogen mustard gas, cyclophosphamide, triamcichon, chlorambucil, busulfan,
nitomin, mannitol-nitrogen mustard gas, amethopterin, 6-mercaptopurin, 5-fluorouracil, cytosinearabinosid.
Podophyllin, actinomycin C, actinomycin D, mithramycin, mitomycin C, adriamycin, bleomycin, asparaginase, ibenzmethycin.
where R=H or CH3.
Phosphorus derivatives of alkaloids corresponding to formula (I) below are of particular interest:
inhere each of R1, R2 and R3 is hydrogen or methoxy, independently of each other or where R1 and R2 or
R2 and R3 together can also represent a methylene dioxy group:
Where R4 and R5 can be H or together with the C-atoms to which they are bonded, form a completely or partially hydrated phenyl- or naphthyl group, which phenyl- or naphthyl group can be unsubstituted or substituted by methoxy, hydroxy, or dioxymethyl, when R7 is H or =O (oxygen atom) or it is an equal ring system bound over a CH2-COCH2-chain, Re is CH and double bonds can be
present in position 1 2 and/or 7,8; or R6 and R7, together with the C and N-atom, to which they are bonded, form a partially hydrated
benzo-or naphtho ring system, which can be unsubstituted or substituted by methoxy, oxo, methyl or
dioxymethyl groups, where the C-N-bond can be missing in position 1, 2 and R4 and R5 mean H;
R8+R9 and R11+R12 mean-CH2-CH2 and if Y=S, X=N and P=2, then R8+R9 and R11+R12 is R2
-CH2-CH2-, -CH2-CH2-O-CH2-CH2-or-CH2-CH2-N-CH2-CH2- ; when Y=S,
X=N, n=2 represents
or (-c2H5)2,
when
Y=S, X=O, n=1 means
when Y=O, X=N, n=1 means
and when
R8 and R9 each mean -CH2-CH2-Cl, R11 H and R10+R12 mean -CH2-CH2-or-CH2-CH2-CH2, when Y=S, X=N, p=1, R -CH2-CH2
The salt formation of the phosphorus derivatives of the alkaloids can be carried out with practically any pharmaceutically acceptable acid, which in itself is sufficiently water-soluble, and thus provides sufficiently water-soluble salts. For economic reasons, hydrochloric acid is preferably used.
The resulting alkaloid thiophosphoric acid amide salts do not differ in their cytostatic or in their pharmacological effectiveness from the corresponding bases. However, dosage preparation of the salts is easier and more exact due to their substantially increased water solubility. Furthermore, no disturbing side effects which can be ascribed to the organic solvents necessary for the corresponding water-insoluble bases can occur.
Salts, especially hydrochloride of berberine of sanguinarine, as well as finally the salts of the alkaloids of the large celandine and other alkaloids come into question as alkaloid salts of formula (II) (compare here also the structure formulas of Figs. 1 to 17).
The cytostatic derivative of the alkaloid can be prepared in one of two ways. The conversion of the alkaloid salts with the cytostatic medium is advantageously carried out in a solvent or solvent mixture at elevated temperature generally at the reflux temperature. Alternatively, the alkaloid base can first be reacted with the thiophosphoric acid amide, after which the reaction product can be converted into the salt, for example by saturating the solvent solution of the alkaloid derivative with HCI (gas and allowing the HCI saturated solution to stand. The reaction of the compound of the alkaloid with the cytostatic and with the acid is advantageously carried out in an organic solvent, where, after salt formation, the actual salt precipitates out or it can be extracted by shaking out with water or hydrous acid into the aqueous solution.Organic solvents used will vary with the alkaloid composition. By way of example, it is noted that benzene, dioxane (anhydrous), and a mixture of ether (anhydrous) and dichloroethane have been used as solvents for thiophosphoric acid-tri-(N-sanguinarinol)-ethyl amide, berberine hydrochloride and a mixture of the alkaloid extract of the great celandine and thiophosphoric acid-triethylene amide.
The alkaloid component of compositions administered in accordance with the invention may contain one or more cytostatic alkaloid derivatives, which will be explained below.
The composition of a preparation, for example, one which consists of alkaloids of Chelidonium majus L., is based on the reaction of the alkaloids with an alkylating substance, such as thiophosphoric acid triaziridide (Thio-TEPA). This substance Thio-TEPA, has three reactive groups, which either bind with the alkaloid molecules or can be substituted by OH or NH2 groups. A whole series of different reaction products can originate in this manner, if this substance binds with an individual, pure alkaloid.
In order to study simpler reactions, individual alkaloids were mixed with Thio-TEPA, cyclophosphamide and other organic compounds in test series. In the case of chelidonin, at least 12 reaction products can be proven by thin-layer chromatography. In order to obtain an exact analysis of these reaction products some were crystallized and isolated by chromatography and subjected to elemental analysis as will be described in the description of the drawings.
Description of the drawings
The following figures of the drawings designate the possible molecular structure based on elemental analysis of the products produced in the reaction on between individual alkaloids and Thio
TEPA, cyclophosphamide and the like. In the description below, the respective alkaloid and phosphorus compounds are described after the numerical designation for the corresponding figure, followed by the actual and calculated elemental analysis for the product.
Fig. 1. Chelilutin+Thiophosphoric acid triaziridide (1 -Chelilutin, 2-thiophosphoric acid triaziridide, 3-chelilutin+thiophosphoric acid triaziridide).
Calculated: C=49.44%; H=6.36%; N=11.53%; P=8.49%: Found: C=49.41%; H=6.34%; N=10.65%; P=8.67%.
Fig. 2. Chelerythrin+Thiophosphoric acid triaziridide C06H69N8O1 5PS.
Calculated: C=63.45%; H=5.56%; N=6.73%; P=2.47%.
Found: C=62.69%; H=5.37%; N=5.37%; P=2.35%.
Fig. 3 Coptisin+Thiophosphoric acid triaziridide C24H2,N4UsPS.
Calculated: C=56.02%; H=5.28%; N=10.88%; P=6.01 9/0; S=6.23%.
Found: C=55.94%; H=5.12%; N=11.10%; P=5.89%; 5=6.10%.
Fig. 4 Chelidonin+Thiophosphoric acid triaziridide C66H75N8O18PS.
Calculated: C=60.82%; H=5.79%; N=6.44%; P=2.37%; S=2.45%.
Found: C=61.41%; H=5.76%; N=5.94%; P=2.40%; S=2.39%.
Fig. 5. Protopine-thiophosphoric acid triaziridide C32H55N11P4S3,
Calculated: C=44.59%; H=6.43%; N=17.87%; P=14.37%; S=11.16%.
Found : C=44.58% ; H=6.14% ; N=17.76% C=44.72%; H=6.30%; N=17.77%; P=14.04%; S=12.71%.
Fig. 6 Reserpine+thiophosphoric triaziridide C72H92N7PSO18,2H2O, m.p. 120-125 .
Theor. : C=59.94% ; H=6.70% ; N=6.79% ; P=2.14% ; S=2.22%.
Found: C=59.89%; H=6.62%; N=6.82%; P-2.21% ; S=2.26%.
Fig. 7 Reserpine+thiophosphoric triaziridide C35H46N3O11PS.
Theor.: C=56.21%; H=6.20%; N=5.61%; P=4.14%; 5=4.28%.
Found: C=56.3%; H=6.22%; N=4.11%.
Fig. 8 Caffeine+thiophosphoric triaziridide C30H42N,5PS05, m.p. 110-112 ; 215-216 .
Theor.: C=46.68%; H=5.48%; N=27.22%; P=4.01 %; S=4.15%.
Found: C=47.37%; H=5.44%; N=27.25%; P=4.02%; S=4.15%.
Fig. 9 Narcotine+thlophosphric triaziridide C28H35n4PSO7, m.p. 225-226
Theor.: C=55.80%; H=5.85% ; N=9.29%; P=5.13%; S=5.29%.
Found: C=55.34%; H=5.69%; N=9.52%; P=4.80%; S=5.29%.
Fig. 10 Aconitine+thiophosphoric triaziridide C74H108N5O22PS, m.p. 197-200 .
Theor. : C=60.02% ; H=7.21% ; N=4.72% ; P=1.09% ; S-2.16%.
Found C=60.02%; H=7.21%; N=4.38%; P=2.09%; S=2.16%.
Fig. 11 Aconitine+thiophosphorictriaziridide C39H69N40r,PS, m.p. 20-211 .
Theor.: C=56.92%; H=7.22%; N=6.80%; P=3.76%; S=3.86%.
Found: C=66.91%; H=7.12%; N=6.89%; P=3.60%; S=3.73%.
Fig. 12 Aonitine+thiophosphoric triaziridide C35H56N4PSO11, m.p. 190-192 .
Theor.: C=54.83%; H=7.19% ; N=7.26%.
Found: C=54.83%; H=6.98%; N=8.74%.
Fig. 13 Pilocarpine+thiophosphoric triaziridide C28H31N3O7.
Fig. 14 Allocryptopine+cyclophosphamide (N,N-bis-(ss-chloroethyl)-N,O-propylenephosphoric acld ester diamlde) C48H85N4O12Cl2P, m.p. 159-160
Theor.: C=8.25%; H=6.29%; N=5.58%; P=3.08%; Cl=7.06%.
Found: C=58.25%; H=6.25%; N=5.40%; P=2.53%; Cl=7.41%; C=54.84% ; H=6.16% ; N=5.62% ; P=2.51% ; Cl=7.26%.
Fig. 15 Protopine+cyclophosphamide (N,N-bis-(P-chlorethyl)-N,0-propylene phosphoric acid ester diamide) C47H55N4O12PCl4, m.p. 239-242 .
Theor.: C=54.24%; H=5.32%; N=5.38%; P=2.97%; Cl=13.62%.
Found: C=54.04%; H=5.25%; N=4.85%; P=2.72%; Cl=10.13% ; C=54.48%; H=5.22%; N=4.69%; P ; Cl=9.9 1%.
Fig. 15a Protopine+cyclophosphamide (N,N-Bis'(ss-chlorethyl)-N',O-propylene phosphoric acid ester diamide) C47H5aN4O12PCl4, m.p. 239-242 .
Theor.: C=54.03%; H=5.69%; N=5.36%: P=2.96%; Cl=13.57%.
Found: C=54.04%; H=5.25%; N=4.85%; P=2.27%; Cl=10.13% ; C=54.48%; H=5.22%; N=4.69%; Cl=9.9 1%.
Fig. 1 5b Protopine+cyclophosphamide (N,N-bis-(ss-chlorethyl)-N',0-propylenephosPhoric acid ester diamide) C47H59N4O12PCL4, m.p. 239-242 .
Theor.: C=54.03%; H=5.69%; N=5.36%; P=2.96%; Cl=13.57%.
Found: C=54.04%; H=5.25%; N=4.85%; P=2.27%; Cl=10.13% ; C=54.48%; H=5.22%; N=4.69%; Cl=9.91%.
Fig. 16 Chelerythrine+cyclophosphamide (N,N-Bis-(ss-chlorethyl)-N',O-propylene phosphoric acid diamide) C2,H3,N309PCI2, m.p. 188-192 .
Theor.: C=49.93%; H=5.74%; N=6.64%; P=4.76%; Cl=10.91%.
Found: C=49.85%; H=5.31%; N=6.06%; P=4.95%; Cl=13.23%; C=49.84%; H=5.24%; N=5.96%; Cl=14.24%.
Fig. 17 Chelidonine+cyclophosphamide (N,N-Bis'(p-chloroethyi)-NtO-propylene phosphoric acid
ester diamide C2,H35N3O,PCI3, m.p. 273276C.
Theor.: C=49.82%; H=5.41 %; N=6.45%; P=4.75%; Cl=16.33%.
Found: C=49.26%; H=5.07%; N=5.12%; P=3.50%; Cl=16.50%.
If a mixture of different alkaloids is mixed with Thio-TEPA, three molecules of different alkaloids may be bound to one Thio-TEPA molecule and thus a large number of components may be synthesized. In this very complex mixture of reaction products, one or more of the reaction products can be responsible for the unique biological activity. Actually, more than 50 points, fluorescent under
UV-light resulted from the separation of the reaction products of Thio-TEPA and the alkaloid extract of
Chelidonium majus L. by two-dimensional thin-layer chromatography. Furthermore, it could be proven that no free ethylene groups of the Thio-TEPA exist in the preparation of the reaction products produced from the alkaloid extract of Chelidonium majus L. reacted with Thio-TEPA.This proof based on chemical analysis, and biological tests to compare the lethal dose of Thio-TEPA which is 1 mg/kg body weight, whereas, a dose of 250 mg/kg body weight of the Thio-TEPA derivative(s) of the alkaloid extract of Chelidonium majus L. is not toxic. Moreover, the preparation has no effect on leukemia 1210 and none on the blood picture. It can be derived from this that the ethylene groups of Thio-TEPA, which are also responsible for its toxic effect, are blocked in the reaction with alkaloids.
It is significant for diagnostic purposes that the hydrochloride of the reaction product(s) of Thio
TEPA and the alkaloid extract of Chelidonium majus L. has the property of being yellow-green fluorescent in ultraviolet light. The excitation frequencies lie within the frequency range from 220 to 490 nm. The spectral width of the fluorescence extends from 410 nm to 665 nm, while the maximum lies at 550 nm. This large spectral width is explained by the fact that the preparation is composed of a group of different alkaloid derivatives. The. visibility limit of the fluorescence phenonemon under UV 366 nm on the plate for thin-layer chromatography lies at a dilutlon of 0.000007 mg/ml,0.0000003 mg per 1 mm2. The preparation also maintains this property in the living body, and thus, the distribution of the preparation could be observed in clinical experiments.
Several clinical case studies are reported below. In each, the hydrochloride salt of the reaction product(s) of Thio-TEPA and the alkaloid extract of Chelidonium majus L. was employed as the preparation for treatment and/or diagnosis.
Case 1
Patient M. B., 64 years old, male; diagnosis: Adenocarcinoma of the rectum with extensive metastatis in the LWS-area. Os il. sin. and Femur dext.
Two treatments were carried out with the preparation. Doses were 140 mg and 160 mg.
Course: Improvement of the general state, slight use of analgesics. Subjective better condition, feeling of warmth in the tumor area rising and falling like waves.
Fluorescence factor: 6 days after completion of the 2nd treatment clearly demarcated fluorescence in the skin area over the tumor and its surrounding area. Also fluorescence in a limited clinical tumor-free skin area. These sites are identical with the areas perceived as warmer. The greater local heat development is objectivized by bands of fever. 13 days later, the fluorescence is much less intense appearing as irregular spotty patterns.
Case 2
Patient R. N., 68 years old, male; diagnosis: Bronchus-Ca li. Upper lobe. Histological: Large cell, infiltrative N. bronchi. Icterus, liver metastasis.
Three times diagnostic applications of the preparation. Total amount 130 mg. Strong fluorescence the size of a dinner plate appeared over the oxyphoid. Questionable fluorescence over the left thorax wall. One week later: No fluorescence can be established.
Case3
Patient M. L., 72 years old, female; diagnosis: Pancreas carcinoma, numerous liver metastasis.
Operation: Probatoria and P.E. from a liver metastasis. Historical: Metastasis of a polymorphous cell, practically mucous forming adenocarcinoma. Constant pain and extreme alkaloid consumption,
Epidural catheter, instillation v. Carbestesin, splanchicus block. Ultrasound: Liver metastasis, large pancreas. A treatment with the preparation, interrupted by giving of placebo.
Palpatoric: Reduction in size of the left liver lobe from 5 to 3 transverse fingers under the rib case.
Metastasis seems to have lessened.
After injection of the preparation, the leukocytes increased to 13000. Fluorescence present a few days after beginning of therapy, medial of the Op wound at one time 30 mm large fluorescence, was later not reproducible.
Case 4
Patient R. M., 73 years old, female, diagnosis: Inoperable stomach carcinoma. Operation:
Probatoria and partial recticulum resection. On the evening before the operation, 2 individual doses of 20 mg of the preparation were administered by i.v.
Histological: Extensive lymph angiosis carcinomatosa of the large reticulum with adenocarcinoma of the stomach. Fluorescence factor: Strong fluorescence of the resec. reticulum part. N.B.: No fluorescence of the large reticulum in the case of the healthy patient. Nodes in the mamma (Cystic mastopathy) is not fluorescent after the preparation.
Case 5
Patient W. S., 26 years old, male; diagnosis: Scar Keloid (over the xyphoid).
0.5 mg of the preparation in 1 ml 0.9% sodium chloride (physiological) solution were administered subcutaneously 50 cm removed from keloid (navel area); approximately one minute after the injection strong fluorescence of the keloid was detected continued for 2 days.
Case 6
Patient N. U., 58 years old, female, diagnosis: Mammary carcinoma. Histological: Carcinosis pleurea, multiple bone metastatis. Condition after recurring pleurae affusions, cytostatic-instillation.
2.5 mg of the preparation was injected. After a short time, fluorescence clear in the case of drain (4 RFI under OP scar) of pleurae effusion with slight fluorescence in the area of the mammaamputation scar.
Summary of clinical results
60 patients have been treated with the preparation "Ukrain", which is a tradename for the hydrochloride salt of the reaction product(s) of thiophosphoric acid triaziridide (Thio-TEPA) and the alkaloid extract of the great celandine (Chelidonium majus L.). Further details of the preparation of this hydrochloride salt are found in my Austrian Patent No. 354,644 granted January 25, 1980. the entire disclosure of which is incorporated herein by reference. 59 of these patients were in an advanced stage of cancer.
In the course of clinical observation, it was revealed that the preparation influences tumor growth in different ways. In no case, does the preparation lead to a bone marrow depression worthy of mention.
The patients could be divided into three groups based on the stage of advancement of the disease. Group I includes 8 patients, 2 female patients with Mamma-Ca; 2 patients with malignant melanoma; 1 patient with basocellular epithelioma; 1 patient with recurrence of a cylinder cell carcinoma of the parotis; 2 patients with alleged mamma-carcinoma, one who did not agree to taking a weight specimen and the other one, on examination, suffering only multiple metastasis of an adenomacarcinoma appeared in the axillary and supraclavicular area, but in both the primary tumor could not be located. A clear remission of the tumor tissue was shown in all of the 8 cases, whereby the tumor tissue reformed partially in reverse sequence to its origin, that is to say, that those metastases which appeared last, were the first to disappear.No necrosis occurred; but next a clear demarcation of the tumor tissue appeared against the surrounding area with retrogression of the local swelling and eventually also of the existing lympho-edema with hindrance of drainage. Then, the tumor nodes slowly became smaller.
A clear effect in the form of subjective sensations was felt by these patients immediately after the first injection, such as:
Subsidal of the pain, in one case occurring 1-2 hours after the injection; feeling of warmth in the tumor, which with one patient was determined as local warming; tension and irritation in the tumor area, heat sensation, tachycardia, slight vertigo or headache; increased urine precipitation; fatigue, depression, nausea and partial depression. These symptoms did not occur at the same time; but with all patients some of the symptoms occurred in individual rhythm after each injection.
From the plots of these effects in one patient, variations in pulse, blood pressure and temperature values could be directly correlated to the occurrence of the named subjective phenomena.
Group Ill included 27 patients: 10 bronchial-Ca; 6 with Mamma-Ca; 2 with Ovarial-Ca; 2 with
Uterus-Ca; 1 with pancreas-Ca; 2 with Rectum-Ca; 1 with stomach-Ca and one with abdominal tumor, which could not be clearly localized because of the progressed state of the primary tumor. In contrast to Group I, an effect was shown here with reference to the tumor as well as with reference to the described side effects. Even with longer treatment time and higher doses, no changes occurred which could be attributed to the preparation Ukrain.
Group II was, so-to-speak an intermediate group and consisted of 25 patients in extremely advanced state of illness: 9 with Mamma-Ca; 7 with bronchial-Ca; rectum-Ca; 2 with osteosarcoma; 1 with prostate-Ca; 1 with tyroid-Ca; 1 with colon-Ca; 1 with stomach-Ca and 1 with abdominal tumor.
The effect of the preparation was very different here. With all these patients, the accompanying symptoms occurred as described in Group I patients, but not so rapidly, after extended treatment.
With these patients, the effect of the preparation on the tumor was not so clearly manifested which may be attributed to the fact that the cancer growth was very advanced. In the case of 2 patients with bronchial-Ca, a short remission of the tumor occurred. In 2 patients, a temporary cessation of growth resulted. In the case of 4 patients with Mamma-Ca, healing of the ulcerations over the metastasis resulted. In the case of other patients, regression of the tumor-caused pain, and partial freedom from pain was attributable to administration of Ukrain. In the case of one female patient with a diffuse infiltrating thyroid gland carcinoma recurrence, the tumor changed in such a way that it could be easily distinguished from the healthy tissue. With almost all these patients, the general condition improved notwithstanding prognosis, even if the tumor growth could not be stopped.
For a better understanding of the description of the foregoing case studies, a representative case of a patient from each group is reported below.
A Group I patient:
Patient T. J., female 40 years old, diagnosis: Malignan melanoma. Histologically verified. (In 1977 a malignant melanoma on the left leg verified and operated on).
In 1980, a lymph node metastasis was found in the left groin, having a size of 5 x 5 cm. The patient was treated with Ukrain. In the course of a three-part treatment, she received a total of 680 mg.
During the first treatment she sustained temporary depression, muscle pain and generally poor feeling, as well as an increase in lymph node metastasis lasting 10 days. After the second treatment the lymph node was only the size of a walnut and after the third treatment it was the size of a bean. It was hard and not well palpable. Her general condition was good.
A Group II patient:
Patient H. G., female, 63 years old, diagnosis: Mamma carcinoma on the left side with supraclavicular lymph node metastasis and bone metastatis. Prior systematic therapy carried out:
Nolvadex from June 1977 to January 1978;
Polychemotherapy with Endoxan, Methotrexate, Flour-Uracil and Prednisolone, later combination therapy with Adriblastin-Endoxan from March 1978 to April 1979. Elipten (Aminoglytethimide) from
April 1979 to January 1980.
Therapy with Ukrain began on February 29, 1980. At the beginning of therapy, a 5x5 cm large ulcerated supraclavicular metastasis was found. Subjective feeling of pressure in the area of the eye as
well as feeling of stress in the left supraclavicular were recorded. The therapy was begun with 2.5 mg.
Right at the beginning of the therapy, the patient noticed a feeling of warmth in the area of the left side of the body, and under the supraclavicular tumor. This feeling of warmth did not reoccur. No more ulcerations were visible in the left supraclavicular after 6 injections. However, the tumor itself was unchanged. Stressful feelings and the feeling of pressure in the area of the eyes that existed for two years disappeared. During the last check on April 8, 1980, the patient was free of such subjective complaints. She complained of moderate weight loss. Local li. supraclavicular was unchanged. No ulcerations-could be proven at that tinge, No pathological iaboratoryindings (blood picture, SMA, serum calcium) could be recorded. No worsening side effects could be determined.
A Group Ill patient:
Patient K. G., female, 58 years old, diagnosis: Adeno-solid ovarian carcinoma, operatively removed. Prior systematic therapy carried out: Endoxan 1200 mg per infusions. Cobalt radiation 4500 rd/g.
Prophylactic therapy with Ukrain was undertaken. No side effects or subjective perceptions during the treatment such as vertigo, temperature increase, tachycardia or depression were experienced. The patient's general feeling, condition, and appetite improved. One month after the beginning of the therapy a node was found in the left breast; and one week later a mammectomy was carried out according to Patey. The histology showed a partially necroticized solid carcinoma. The treatment with Ukrain was discontinued.
To determine the effect of the mechanism of therapeutic and diagnostic capacity of Ukrain, studies were carried out concerning the immuno-stimulating effect of Ukrain in vitro in the so-calied Iymphocyte-transformation test, and results of the studies are reported in the following tables.
Generally, lymphocytes are known to be immunocompetent when they are capable of recognizing the specific antigen, or if they are capable of reacting with it. Such cells are called immunocytes and their successors are called im munoblasts.
The formation of immunoblasts can also be carried out in vitro. The immunoblasts have a size of 20-30 u, whereas, normal lymphocytes have a size of only 5-15 u. In the following immunological tests, isolated lymphocytes of healthy humans and of guinea pigs were used for the blast transformation after the addition of Ukrain. A mixture of the compound known under the tradename
Ficoll 4000 and EDTA was used for the isolation (0.9 EDTA+O.1 Ficoll 4000).
The isolated lymphocytes were grown in vitro in Parker solution, with an addition of 1.6 CLg. 0.16 y9 and 0.016 g. At the same time lymphocytes were bred in Parker solution with 5 jug/ml of the
unspecific stimulator phytohemaglutinin (PHA) and without an additive as a control run. In order to avoid solonization of bacteria, effective amounts of antibiotics, penicillin, streptomycin and nystatin, were added. The cultures were incubated at 370C and the number of transformed lymphocytes was
counted daily under the microscope for 3 days.
100 lymphocytes were counted out in each preparation and those lymphocytes which were
larger than 1 5,u (from humans) and larger than 20 y in the case of guinea pigs, were evaluated as being transformed. In all cases. before the beginning of breeding, the number of transformed cells was not larger than 10.1%. The tests were carried out with the lymphocytes of 10 healthy humans and 10 healthy guinea pigs.
Since in the case of a cure with Ukrain the average single dose amounts to 10 mg (the mean individual dose of Ukrain used in these experiments being 16 mg), the dose of Ukrain was actually 1/10000; 1/100000 and 1/1000000 of the amount. The results are summarized in the following
Tables I and II:
Table I
Percentage of transformed guinea pigs lymphocytes.
Culture-medium Breeding time
No. with additive 24 hrs. 48 hrs. 72 hrs.
1. 1.6* 48.6 45.6 40.2
0.16* 42.3 29.3 28.5
0.016* 35.6 33.6 25.0
PHA 32.2 28.3 27.9
Without stimulator 19.2 15.3 1.8
2. 1.6* 53.9 30.2 18.3
0.16* 48.7 32.2 32.0 (?)
0.016* 27.3 30.2 18.5
PHA 20.8 17.2 17.5
Without stimulator 13.3 12.2 1 9.2 (7) 3. 1.6* 50.2 48.3 42.8
0.16* 49.3 51.1 39.9
0.016* 41.0 29.3 30.1
PHA 32.5 29.8 22.3
Without stimulator 18.0 11.2 10.3
4. 1.6* 55.6 42.3
0.16* 50.8 40.7 43.8
0.016* 41.2 38.5 39.5
PHA 33.2 27.0 18.0
Without stimulator 18.2 18.0 1 6.2 5. 1.6* 51.3 43.5 31.5
0.16* 48.2 33.2 33.5 0.016* 39.9 31.5 30.2
PHA 33.4 20.3 11.3
Without stimulator 12.5 12.5 8.4
6. 1.6* 58.5 57.9 41.8
0.16* 48.3 50.0 43.2
0.016* 40.1 35.2 30.0
PHA 30.2 22.1 17.3
Without stimulator 19.0 18.2 13.5
7. 1.6* 43.3 41.2 39.8
0.16* 42.3 36.6 36.2 0.016* 41.2 37.2 35.5
PHA 33.3 33.4 27.2
Without stimulator 15.1 16.1 13.2
8. 1.6* 48.7 45.1 40.3
0.16* 43.1 39.2 31.1
0.016* 35.6 29.8 24.2
PHA 31.3 27.0 24.3
Without stimulator 12.2 10.1 10.5
Table I (cont.).
9. 1.6* 53.3 51.5 41.2
0.16* 49.6 47.2 42.2
0.016* 39.2 36.7 34.6
PHA 38.3 32.8 25.2
Without stimulator 18.1 16.7 11.3
10 1.6* 56.2 53.6 40.7
0.16* 49.3 42.8 34.5
0.016* 39.8 37.3 28.3
PHA 34.2 33.2 27.5
Without stimulator 12.0 10.2 8.4 *Amount of Ukrain in units of g/ml.
Table II
Percentage of transformed human lymphocytes.
Culture-medium Breeding time
No. with additive 24 hrs. 48 hrs. 72 hrs.
1. 1.6* 47.2 43.4 41.2
0.16* 43.8 39.2 38.6
0.016* 39.6 36.7 35.2
PHA 5,ug/ml 36.6 24.8 20.8
Without stimulator 11.1 9.2 9.0
2. 1.6* 49.9 41.2 37.2
0.16* 43.2 40.3 33.2
0.016* 38.6 36.2 26.8 PHA 5 ygiml 31.2 28.0 21.2
Without stimulator 18.4 14.1 8.4
3. 1.6* 19.1 18.8 16.2
0.16* 19.5 18.2 15.3
0.016* 14.2 15.3 13.2 PHA5g/ml 33.1 28.2 14.1
Without stimulator 10.7 9.3 15.3
4. 1.6* 43.9 42.8 39.4
0.16* 41.2 40.6 41.2
0.016* 33.6 32.1 31.2
PHA 5,ug/ml 40.2 33.6 28.3
Without stimulator 13.6 12.3 10.8
5. 1.6* 53.3 51.5 47.8
0.16* 48.6 43.6 41.0
0.016* 37.2 37.8 36.2
PHA 5 g/ml 36.4 28.5 25.4
Without stimulator 15.3 14.4 12.8
6. 1.6* 55.5 53.4 51.5
0.16* 51.2 49.1 47.3
0.016* 43.2 36.2 36.0 PHA 5 ssg/ml 37.1 36.2 34.7
Wlthout stimultor 19.3 18.4 16.5
7. 1.6* 48.6 46.8 42.5
0.16* 47.2 45.2 24.3
0.016* 39.8 32.0 21.2
PHA 5 g/ml 30.1 26.8 19.0
Without stimulator 14.7 13.1 8.5
Table 11 (cont.).
8. 1.6* 52.3 37.4 21.8
0.16* 48.3 28.3 19.3
0.016* 41.2 19.4 17.4 PHA 5 yg/ml 37.3 19.5 20.1
Without stimulator 9.0 8.3 8.2
9. 1.6* 47.2 32.8 29.1
0.16* 43.4 36.4 34.2
0.016* 38.6 25.0 20.0 PHA 5 uglml 36.6 28.6 21.4
Without stimulator 1 5.3 13.3 10.7
10 1.6* 48.3 37.4 33.3
0.16* 43.4 41.2 36.8
0.016* 37.1 36.2 29.1
PHA 5 uglml 30.0 19.4 18.4
Without stimulator 9.3 9.6 5.3
*Amount of Ukrain in units of yg/ml.
In the test a statistically significant difference was shown between the number of transformed lymphocytes of humans and of animals and of control groups absent Ukrain. The conclusion can be drawn from this that the preparation Ukrain has an immunological effectiveness and stimulates the human defense mechanism. Clear transformation of lymphocytes did not occur in only one out of 10 cases (see Table II, No. 3, where human lymphocytes were tested. In the case of patient no. 3, under certain circumstances as "in vitro equivalent" could exist for the clinical phenomenon, in which individual patients showed no reaction at all to Ukrain).
Although no clear lymphocytes transformation was effected by Ukrain in the case of test person no. 3, a higher lymphocyte transformation was obtained with all other patients than with PHA.
Finally, the conventional Agargel electrophoresis using 0.05 mg Ukrain, was run on Agargel (Corensen buffer+NaCI) and was put into a small notch and lasted 4 hours at 70 volts and 2 mA, a filter paper was pressed on the surface, the start and the polarity were marked; a fluorescent band directed to a negative pole was defected under UV-lamp. The fluorescent fractions were positively charged.
It is apparent from the preceding that the subject preparations or compounds described at the beginning of this specification can be used for diagnosing as well as for the therapeutic treatment of tumors of all types, and also for diagnosing and treating infectious diseases. According to the invention, the fluorescent effect of the Ukrain preparations is of great significance. For diagnosis, it is thus possible for rapid early detection, after the injection of the preparation(s), by virtue of its accumulation in the diseased tissue area. Rapid and reliable diagnosis can be based on that accumulation by observing decomposition and the rate of decomposition of the injection fluid in the injected area and/or by observing the localization of same in the diseased area, for example, in the tumor tissue.This observation extends to all endoscopic methods including bronchoscopy, mediastinoscopy, thorascopy, esophagoscopy, Otorhinoscopy, laryngoscopy, rectoscopy, proctoscopy among others, where for example, cold light is repiaced by UV-light.
In this connection, the preparation may be radioactively labelled with radioactive isotopes, and then the diagnostic method includes measuring radioactivity of the accumulated radioactively labelled preparation in a known manner with suitable detectors; and accumulation can be recorded for example with gamma-ray scanners. In addition to labelling of the described preparations with fluorescent materials and radioactive isotopes, the preparations may be doped with radiation-absorbing compounds or radicals, so that accumulation of the doped preparation may be detected in a certain tissue area due to the increased absorption of X-radiation there.
It is especially noteworthy in this connection that in the case of very many patients, infections disappeared after the first Ukrain injection. Among them were stubborn mycosis which previously had not responded to any therapy, cases of chronic bronchitis and throat inflammations of unclear genesis, as well as other viral and bacterial diseases, according to the treating physicians. Thus, the previous results also suggest the stimulation of lymphocytes to immunocytes by means of the preparation; such stimulation is equivalent to the production of the so-called killer-cells which destroy the affected tissue or the tissue foreign to the body, or virus which has penetrated healthy cells, and/or bacteria, fungi, and the like. Therefore, the healing of tumor diseases, as well as viral diseases, bacterial diseases and fungal diseases, and in addition a healing of polyarthritis can be realized.
Claims (25)
1. A method of treating a diseased mammal, said mammal diseased by the multiplication of tumor cells or by the multiplication of foreign organisms, comprising administering to said diseased mammal a pharmaceutically effective amount of a pharmaceutically acceptable cytostatic alkaloid derivative, said pharmaceutically acceptable cytostatic alkaloid derivative accumulating in said tumor cells or said foreign organisms, and at least retarding the multiplication of said tumor cells or said foreign organisms.
2. The method of Claim 1, including destroying said tumor cells or said foreign organisms.
3. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is a water-soluble salt.
4. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is administered intravenously.
5. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is administered by injection.
6. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is a pharmaceutically acceptable cytostatic alkaloid extract of Chelidonium majus L.
7. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from an alkaloid selected from the group consisting of chelilutin, chelerythrin, coptisin, chelidonin, protopine, reserpine, caffeine, narcotine, aconitine, allocryptopine, protopine, and admixtures thereof.
8. The method of Claim 7, wherein said pharmaceutically acceptable cytostatic alkaloid derivative
is derived from an admixture of said alkaloids.
9. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from chelitutin.
10. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from chelerythrln.
11. The method of Claim 1 , wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from coptisin.
12. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from chelidonin.
1 3. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from protopine.
14. The method of Claim 1 , wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from reserpine.
1 5. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from caffeine.
1 6. The method of Claim 1 , wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from narcotine.
1 7. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from aconitine.
18. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from allocryptopine.
1 9. The method of Claim 1, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is derived from protopine.
20. A method of diagnosing a diseased mammal, said mammal diseased by the multiplication of tumor cells comprising administering to said diseased mammal a pharmaceutically effective amount of a pharmaceutically acceptable cytostatic alkaloid derivative, said pharmaceutically acceptable cytostatic alkaloid derivative accumulating in said tumor cells; and detecting that pharmaceutically acceptable cytostatic alkaloid derivative which has accumulated in said tumor cells.
21. The method of Claim 20, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is administered by injection.
22. The method of Claim 20, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is administered intravenously.
23. The method of Claim 20, wherein said pharmaceutically acceptable cytostatic alkaloid derivative is a pharmaceutically acceptable alkaloid extract of Cheiidonium majus L.
24. A pharmaceutically acceptable cytostatic alkaloid derivative for use in treating or diagnosing a mammal diseased by the multiplication of tumor cells or by the multiplication of foreign organisms.
25. A composition for use in treating a diseased mammal according to the method of any one of
Claims 1-23.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19813128018 DE3128018A1 (en) | 1981-07-13 | 1981-07-13 | "METHOD FOR DIAGNOSTICING AND FOR THE THERAPEUTIC TREATMENT OF TUMORS AND / OR INFECTIOUS DISEASES OF DIFFERENT TYPES WITH PREPARATIVE USE OF ALKALOID COMPOUNDS OR THEIR SALTS" |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2110533A true GB2110533A (en) | 1983-06-22 |
GB2110533B GB2110533B (en) | 1986-06-11 |
Family
ID=6136994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB08220293A Expired GB2110533B (en) | 1981-07-13 | 1982-07-13 | Compositions containing alkaloid derivatives |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0083600B1 (en) |
JP (1) | JPS58501074A (en) |
AU (1) | AU568483B2 (en) |
DE (3) | DE3128018A1 (en) |
DK (1) | DK33283D0 (en) |
FI (1) | FI73131C (en) |
GB (1) | GB2110533B (en) |
WO (1) | WO1983000486A1 (en) |
YU (1) | YU44969B (en) |
ZA (1) | ZA824983B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981512A (en) * | 1995-06-01 | 1999-11-09 | Nowicky; Wassyl | Means for treating radiation injuries |
WO2002013803A2 (en) * | 2000-08-11 | 2002-02-21 | Arch Development Corporation | Chelerythrine-based therapies for cancer |
DE10043615A1 (en) * | 2000-09-05 | 2002-03-14 | Erich Schneider | Free-piston engine, e.g. double-piston engine with pistons connected by common piston rod with sliding spring-mounted driver element for direct force transmission without losses |
WO2003041721A1 (en) * | 2001-11-15 | 2003-05-22 | Nowicky Wassili | Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
WO2006053649A1 (en) * | 2004-11-19 | 2006-05-26 | Nowicky Wassili | Method for the detection of cancer |
WO2006053680A1 (en) * | 2004-11-19 | 2006-05-26 | Nowicky Wassili | Ex vivo cancer diagnostic method |
WO2007073919A3 (en) * | 2005-12-28 | 2007-11-22 | Nowicky Wassili | Method and kit for the detection of cancer |
US7795434B2 (en) | 2003-03-18 | 2010-09-14 | Wassyl Nowicky | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments |
WO2015144900A1 (en) * | 2014-03-27 | 2015-10-01 | Nowicky Wassili | Diagnostic method for early detection of cancer |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2623504B1 (en) * | 1987-11-25 | 1990-03-09 | Adir | NOVEL N- (VINBLASTINOYL-23) DERIVATIVES OF 1-AMINO METHYLPHOSPHONIC ACID, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
HUP9601096A2 (en) * | 1996-04-26 | 1998-01-28 | János Aradi | Pharmaceutical and medicine composition of anti-hiv activity based on medicinal plants |
US6673814B2 (en) | 1997-08-19 | 2004-01-06 | Emory University | Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents |
AU8414098A (en) | 1997-08-19 | 1999-03-08 | Emory University | Noscapine derivatives, useful as anticancer agents |
AT408719B (en) * | 2000-03-22 | 2002-02-25 | Nowicky Wassili | AGENT FOR TREATING HEPATITIS C |
JP4753114B2 (en) * | 2004-12-28 | 2011-08-24 | 国立大学法人 琉球大学 | Anti-tumor cell agent, pharmaceutical composition and diagnostic agent |
EP2192114A1 (en) * | 2008-12-01 | 2010-06-02 | Universite victor Segalen Bordeaux II | bis [O-(14-benzoylaconine-8-yl)] esters |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3865830A (en) * | 1969-06-16 | 1975-02-11 | Nikolai Mikhailovich Turkevich | Thiophosphamide derivatives of isoquinoline alkaloids, method of producing and application thereof |
JPS5512003B2 (en) * | 1973-01-24 | 1980-03-29 | ||
AT354644B (en) * | 1975-12-19 | 1980-01-25 | Nowicky Wassili | METHOD FOR PRODUCING NEW SALTS OF ALKALOID DERIVATIVES FROM THIOPHOSPHORIC ACID |
AT377988B (en) * | 1976-06-28 | 1985-05-28 | Nowicky Wassili | METHOD FOR PRODUCING NEW PHOSPHORUS DERIVATIVES FROM ALKALOIDS |
DE4339730C2 (en) * | 1993-11-22 | 1996-07-11 | Eisenmann Kg Maschbau | Bogie hearth furnace for firing ceramics or the like |
-
1981
- 1981-07-13 DE DE19813128018 patent/DE3128018A1/en not_active Withdrawn
-
1982
- 1982-07-08 WO PCT/AT1982/000021 patent/WO1983000486A1/en active IP Right Grant
- 1982-07-08 JP JP57502047A patent/JPS58501074A/en active Granted
- 1982-07-08 AU AU86814/82A patent/AU568483B2/en not_active Expired
- 1982-07-08 DE DE8282901956T patent/DE3277726D1/en not_active Expired
- 1982-07-08 DE DE82AT8200021T patent/DE3248943D2/en not_active Expired
- 1982-07-08 EP EP82901956A patent/EP0083600B1/en not_active Expired
- 1982-07-13 YU YU1529/82A patent/YU44969B/en unknown
- 1982-07-13 GB GB08220293A patent/GB2110533B/en not_active Expired
- 1982-07-13 ZA ZA824983A patent/ZA824983B/en unknown
-
1983
- 1983-01-28 DK DK0332/83A patent/DK33283D0/da unknown
- 1983-03-07 FI FI830760A patent/FI73131C/en not_active IP Right Cessation
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981512A (en) * | 1995-06-01 | 1999-11-09 | Nowicky; Wassyl | Means for treating radiation injuries |
AT407833B (en) * | 1995-06-01 | 2001-06-25 | Nowicky Wassyl Dr | AGENTS FOR THE TREATMENT OF RADIATION DAMAGES |
WO2002013803A2 (en) * | 2000-08-11 | 2002-02-21 | Arch Development Corporation | Chelerythrine-based therapies for cancer |
WO2002013803A3 (en) * | 2000-08-11 | 2003-03-13 | Arch Dev Corp | Chelerythrine-based therapies for cancer |
DE10043615A1 (en) * | 2000-09-05 | 2002-03-14 | Erich Schneider | Free-piston engine, e.g. double-piston engine with pistons connected by common piston rod with sliding spring-mounted driver element for direct force transmission without losses |
WO2003041721A1 (en) * | 2001-11-15 | 2003-05-22 | Nowicky Wassili | Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
CN100436462C (en) * | 2001-11-15 | 2008-11-26 | 挪威奇·华兹 | Reaction method of biological alkali, reaction product and use thereof |
US7795434B2 (en) | 2003-03-18 | 2010-09-14 | Wassyl Nowicky | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments |
WO2006053649A1 (en) * | 2004-11-19 | 2006-05-26 | Nowicky Wassili | Method for the detection of cancer |
WO2006053680A1 (en) * | 2004-11-19 | 2006-05-26 | Nowicky Wassili | Ex vivo cancer diagnostic method |
WO2007073919A3 (en) * | 2005-12-28 | 2007-11-22 | Nowicky Wassili | Method and kit for the detection of cancer |
WO2015144900A1 (en) * | 2014-03-27 | 2015-10-01 | Nowicky Wassili | Diagnostic method for early detection of cancer |
Also Published As
Publication number | Publication date |
---|---|
DE3128018A1 (en) | 1983-04-07 |
JPS58501074A (en) | 1983-07-07 |
DE3248943D2 (en) | 1984-10-04 |
WO1983000486A1 (en) | 1983-02-17 |
DK33283D0 (en) | 1983-01-28 |
FI73131C (en) | 1987-09-10 |
GB2110533B (en) | 1986-06-11 |
FI830760L (en) | 1983-03-07 |
YU44969B (en) | 1991-06-30 |
YU152982A (en) | 1986-04-30 |
FI830760A0 (en) | 1983-03-07 |
AU568483B2 (en) | 1988-01-07 |
JPH0326199B2 (en) | 1991-04-10 |
EP0083600B1 (en) | 1987-11-25 |
AU8681482A (en) | 1983-02-22 |
DE3277726D1 (en) | 1988-01-07 |
FI73131B (en) | 1987-05-29 |
EP0083600A1 (en) | 1983-07-20 |
ZA824983B (en) | 1984-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4816462A (en) | Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds | |
GB2110533A (en) | Compositions containing alkaloid derivatives | |
US4970212A (en) | Method of treating human illnesses which compromise the ability to mount an effective immunological response | |
AU700502B2 (en) | Zwitterionic compositions and methods as biological response modifiers | |
US5723465A (en) | Inhibitors for cell adhesion and cellular infiltration | |
CA2914501C (en) | Compositions and methods for reducing or preventing metastasis | |
KR20100031759A (en) | Treatment of melanoma | |
RU2004135307A (en) | EPOTHYLON DERIVATIVE FOR THE TREATMENT OF HEPATOMA AND OTHER CANCER DISEASES | |
CA2593202A1 (en) | Quaternary alkaloid derivatives of chelidonium majus l | |
US4468393A (en) | Treatment of arthritis | |
Jiang et al. | Activity of camptothecin, harringtonin, cantharidin and curcumae in the human tumor stem cell assay | |
AU2004222661B2 (en) | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments | |
RU2312687C1 (en) | Method for applying combined skin melanoma treatment | |
Minton et al. | The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer. | |
Rainer et al. | Effectiveness of Postoperative Adjuvant Therapy with Cytotoxic Chemotherapy (Cytosine Arabinoside, Mitomycin C, 5-Fluorouracil) or Immunotherapy (Neuraminidase-Modified Allogeneic Cells) in the Prevention of Recurrence of Duke’s B and C Colon Cancer | |
Bertrand et al. | Nedocromil sodium inhibits IgE-and IgG-related antigen-induced contraction in guinea-pig trachea | |
Murthy et al. | Pre‐, peri‐, and postoperative chemotherapy for breast cancer: Is one better than the other? | |
Kende et al. | Modification of the response of autochthonous Moloney sarcoma virus-induced tumors to poly I: C by DEAE-dx | |
WO2022164901A1 (en) | Enhanced anti-proliferative and antitumor immune effects of mitochondria-targeted hydroxyurea | |
Kim et al. | The growth inhibitiory effect of new pyrrolo [1, 2-α] benzimidazole derivatives on human gastric cancer cells | |
JPH03271222A (en) | Antitumor agent by anti-promoter action | |
US20100227791A1 (en) | Compounds Having Antitumor Activity | |
JPS60500291A (en) | Arthritis treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE20 | Patent expired after termination of 20 years |
Effective date: 20020712 |